| Bioactivity | Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban dihydrochloride can be used for the research of myocardial infarction (MI)[1]. |
| Target | IC50: 45 nM (αIIbβ3) |
| In Vivo | Zalunfiban dihydrochloride (1~3.86 mg/kg; s.c.; 24 hours) makes platelet aggregation performed[1].Zalunfiban dihydrochloride (1~3.86 mg/kg; i.m.; 4.5 hours) leads to the onset of high-grade inhibition of platelet aggregation within 15–30 minutes that lasts from ~2 to >4.5 hours in a dose dependent manner[1]. Animal Model: |
| Name | Zalunfiban dihydrochloride |
| Formula | C16H20Cl2N8O2S |
| Molar Mass | 459.35 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Vootukuri S, et al. Preclinical Studies of RUC-4, a Novel Platelet αIIbβ3 Antagonist, in Non-Human Primates and With Human Platelets. J Clin Transl Sci. 2019;3(2-3):65-74. |
Zalunfiban dihydrochloride
CAS: F: C16H20Cl2N8O2S W: 459.35
Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet αIIbβ3 antagonist (IC50=45 nM). Zalunfiban dihydroc
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.